Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma

Archives of Ophthalmology

Volumn 123, Issue 2, 2005, Pages 220-224

  Dan, Jacob ^a,b   Belyea, David ^b   Gertner, Gregory ^b   Leshem, Israel ^c   Lusky, Moshe ^d   Miskin, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Maccabi Ophthalmic Surgical Center   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; PILOCARPINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROTEIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLAUCOMA; HUMAN; MALE; PRIORITY JOURNAL; RANK SUM TEST;

AGED; AQUEOUS HUMOR; CATARACT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXFOLIATION SYNDROME; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITORS;

EID: 13244259217     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.2.220     Document Type: Article

References (33)

1. Javitt JC, McBean AM, Nicholson GA, et al. Undertreatment of glaucoma among black Americans. N Engl J Med. 1991;325:1418-1422.
2. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. JAMA. 1991;266:369-374.
3. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
4. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
5. Grierson I. What is open angle glaucoma? Eye. 1987;1:15-28.
6. Fine BS, Yanoff M, Stone RA. A clinicopathologic study of four cases of primary open-angle glaucoma compared to normal eyes. Am J Ophthalmol. 1981;91:88-105.
7. Tawara A, Varner HH, Hollyfield JG. Distribution and characterization of sulfated proteoglycans in the human trabecular tissue. Invest Ophthalmol Vis Sci. 1989;30:2215-2231.
8. Yun AJ, Murphy CG, Polansky JR, Newsome DA, Alvarado JA. Proteins secreted by human trabecular cells: glucocorticoid and other effects. Invest Ophthalmol Vis Sci. 1989;30:2012-2022.
9. Masos T, Dan JA, Miskin R. Plasminogen activator inhibitor-1 (PAI-1) is localized in the adult rodent eye exclusively in the tips of the ciliary processes. Invest Ophthalmol Vis Sci. 2000;41:1006-1011.
10. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis. 1991;5:197-206.
11. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis. 1995;9:263-276.
12. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792-1801.
13. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
14. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072.
15. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997;9:714-724.
16. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003;160:781-791.
17. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16:207-216.
18. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J. 1998;19(suppl C):C39-C43.
19. Cesari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol. 1999;19:1378-1386.
20. Festa A, D'Agostino RJ, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
21. Venugopal B, Sharon R, Abramovitz R, Khasin A, Miskin R. Plasminogen activator inhibitor-1 in cardiovascular cells: rapid induction after injecting mice with kainate or adrenergic agents. Cardiovasc Res. 2001;49:476-483.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
23. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
24. Krause U, Raunio V. Proteins of the normal human aqueous humor. Ophthalmologica. 1969;159:178-185.
25. Mori M, Araie M, Sakurai M, et al. Effects of pilocarpine and tropicamide on blood-aqueous barrier permeability in man. Invest Ophthalmol Vis Sci. 1992;33:416-423.
26. Kuchle M, Ho TS, Nguyen NX, Hannape E, Naumann GO. Protein quantification and electrophoresis in aqueous humor of pseudoexfoliation eyes. Invest Ophthalmol Vis Sci. 1994;35:748-752.
27. Mori F, Ishiko S, Abiko T, et al. Changes in corneal and lens autofluorescence and blood glucose levels in diabetics: parameters of blood glucose control. Curr Eye Res. 1997;16:534-538.
28. Wang Y, Taylor DM, Smalley DM, Cone RE, O'Rourke J. Increased basal levels of free plasminogen activator found in human aqueous humor. Invest Ophthalmol Vis Sci. 1994;35:3561-3566.
29. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based-linked immunosorbent assay. Blood. 1988;71:220-225.
30. Smalley DM, Fitzgerald JE, Taylor DM, Cone RE, O'Rourke J. Tissue plasminogen activator activity in human aqueous humor. Invest Ophthalmol Vis Sci. 1994;35:48-53.
31. Bernatchez SF, Tabatabay C, Belin D. Urokinase-type plasminogen activator in human aqueous humor. Invest Ophthalmol Vis Sci. 1992;33:2687-2692.
32. Ortego J, Escribano J, Coca-Prados M. Gene expression of proteases and protease inhibitors in the human ciliary epithelium and ODM-2 cells. Exp Eye Res. 1997;65:289-299.
33. Escribano J, Ortego J, Coca-Prados M. Isolation and characterization of cell-specific cDNA clones from a subtractive library of the ocular ciliary body of a single normal human donor: transcription and synthesis of plasma proteins. J Biochem (Tokyo). 1995;118:921-931.